Clinical Trial Update: An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia [Phase 2]

View source ↗

Summary

Pfizer's Phase 2 outpatient trial evaluating PF-02545920 as an adjunctive treatment for schizophrenia was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• PF-02545920

Snippet

Sponsor: Pfizer | Conditions: Schizophrenia | Phase 2 | Status: TERMINATED | Results posted: 2016-08-22